{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T14:20:07Z","timestamp":1704982807770},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,12,2]],"date-time":"2007-12-02T00:00:00Z","timestamp":1196553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s00108-007-1981-z","type":"journal-article","created":{"date-parts":[[2007,11,30]],"date-time":"2007-11-30T12:51:00Z","timestamp":1196427060000},"page":"106-113","source":"Crossref","is-referenced-by-count":1,"title":["Pharmakotherapie der Adipositas"],"prefix":"10.1007","volume":"49","author":[{"given":"A.","family":"Hamann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,2]]},"reference":[{"key":"1981_CR1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","volume":"106","author":"Apfelbaum","year":"1999","unstructured":"Apfelbaum M, Vague P, Ziegler O et al. (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106: 179\u2013184","journal-title":"Am J Med"},{"key":"1981_CR2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1463-1326.2006.00602.x","volume":"8","author":"Blonde","year":"2006","unstructured":"Blonde L, Klein EJ, Han J et al. (2006) Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8: 436\u2013447","journal-title":"Diabetes Obes Metab"},{"key":"1981_CR3","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121\u20132134","journal-title":"N Engl J Med"},{"key":"1981_CR4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/er.2006-0041","volume":"27","author":"Foster-Schubert","year":"2006","unstructured":"Foster-Schubert KE, Cummings DE (2006) Emerging therapeutic strategies for obesity. Endocr Rev 27: 779\u2013793","journal-title":"Endocr Rev"},{"key":"1981_CR5","unstructured":"Hauner H, Buchholz G, Hamann A et al. (2007) Evidenzbasierte Leitlinie \u2013 Pr\u00e4vention und Therapie der Adipositas. Deutsche Adipositas-Gesellschaft, Deutsche Diabetes-Gesellschaft, Deutsche Gesellschaft f\u00fcr Ern\u00e4hrung, Deutsche Gesellschaft f\u00fcr Ern\u00e4hrungsmedizin, http:\/\/www.adipositas-gesellschaft.de"},{"key":"1981_CR6","first-page":"163","volume":"25","author":"Hauner","year":"2000","unstructured":"Hauner H, Wechsler JG, Kluthe R et al. (2000) Qualit\u00e4tskriterien f\u00fcr ambulante Adipositasprogramme. Akt Ernaehr Med 25: 163\u2013165","journal-title":"Akt Ernaehr Med"},{"key":"1981_CR7","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (2006) Nutzenbewertung nichtmedikament\u00f6ser Behandlungsstrategien bei Patienten mit Bluthochdruck: Gewichtsreduktion. Abschlussbericht A05\/21-A. http:\/\/www.iqwig.de"},{"key":"1981_CR8","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"James","year":"2000","unstructured":"James WP, Astrup A, Finer N et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119\u20132125","journal-title":"Lancet"},{"key":"1981_CR9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393\u2013403","journal-title":"N Engl J Med"},{"key":"1981_CR10","first-page":"494","volume":"Obes","author":"Kopelman","year":"2007","unstructured":"Kopelman P, Bryson A, Hickling R et al. (2007) Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 31: 494\u2013499","journal-title":"Int J"},{"key":"1981_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1370\/afm.343","volume":"3","author":"Levri","year":"2005","unstructured":"Levri KM, Slaymaker E, Last A et al. (2005) Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 3: 457\u2013461","journal-title":"Ann Fam Med"},{"key":"1981_CR12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1464-5491.2000.00320.x","volume":"17","author":"Manley","year":"2000","unstructured":"Manley SE, Stratton IM, Cull CA et al. (2000) Effects of three months\u2018 diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group. Diabet Med 17: 518\u2013523","journal-title":"Diabet Med"},{"key":"1981_CR13","first-page":"CD004096","volume":"164","author":"Norris","year":"2005","unstructured":"Norris SL, Zhang X, Avenell A et al. (2005) Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 164: CD004096","journal-title":"Cochrane Database Syst Rev"},{"key":"1981_CR14","first-page":"CD004094","volume":"3","author":"Padwal","year":"2004","unstructured":"Padwal R, Li SK, Lau DC (2004) Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 3: CD004094","journal-title":"Cochrane Database Syst Rev"},{"key":"1981_CR15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761\u2013775","journal-title":"JAMA"},{"key":"1981_CR16","first-page":"517","volume":"Obes","author":"Ruof","year":"2005","unstructured":"Ruof J, Golay A, Berne C et al. (2005) Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes (Lond) 29: 517\u2013523","journal-title":"Int J"},{"key":"1981_CR17","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P et al. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660\u20131672","journal-title":"Lancet"},{"key":"1981_CR18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T et al. (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352: 167\u2013172","journal-title":"Lancet"},{"key":"1981_CR19","first-page":"138","volume":"Obes","author":"Toplak","year":"2007","unstructured":"Toplak H, Hamann A, Moore R et al. (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond) 31: 138\u2013146","journal-title":"Int J"},{"key":"1981_CR20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1463-1326.2005.00483.x","volume":"7","author":"Toplak","year":"2005","unstructured":"Toplak H, Ziegler N, Keller F et al. (2005) X-PERT: Orlistat reduces weight in obese subjects receiving a mildly reduced-caloric diet or moderate diet. Early response to treatment predicts weight maintenance. Diabetes Obes Metab 7: 699\u2013708","journal-title":"Diabetes Obes Metab"},{"key":"1981_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L (2004) XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27: 155\u2013161","journal-title":"Diabetes Care"},{"key":"1981_CR22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"Tuomilehto","year":"2001","unstructured":"Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343\u20131350","journal-title":"N Engl J Med"},{"key":"1981_CR23","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"Van","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ et al. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389\u20131397","journal-title":"Lancet"},{"key":"1981_CR24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2337\/diacare.28.4.942","volume":"28","author":"Vettor","year":"2005","unstructured":"Vettor R, Serra R, Fabris R et al. (2005) Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 28: 942\u2013949","journal-title":"Diabetes Care"},{"key":"1981_CR25","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","volume":"353","author":"Wadden","year":"2005","unstructured":"Wadden TA, Berkowitz RI, Womble LG et al. (2005) Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353: 2111\u20132120","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1981-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-007-1981-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1981-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:12:06Z","timestamp":1558584726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-007-1981-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["1981"],"URL":"https:\/\/doi.org\/10.1007\/s00108-007-1981-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,2]]}}}